FDA Approves New Oral Ertugliflozin For T2D


eMediNexus    26 December 2017

Another SGLT2 inhibitor, ertugliflozin, was approved for glycemic control in adults with type 2 diabetes. The once-daily, single therapy oral agent was approved as an adjunct to diet and exercise and will be available in two doses, 5mg and 15mg tablets. The approval also encompasses two ertugliflozin combination treatments, including combination sitagliptin, as well as combination metformin therapy.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.